Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.

Our data provide clues to the pathways contributing to the glandular and non-glandular manifestations of SS and to potential therapeutic targets for different SS subtypes. In addition, our analysis highlights the need for further exploration of altered metabolism and mitochondrial dysfunction in the context of SS subtypes.